BioCentury
ARTICLE | Clinical News

N91115: Phase II started

May 23, 2016 7:00 AM UTC

Nivalis began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate 400 mg oral N91115 twice daily for 12 weeks plus Kalydeco ivacaftor in about 20 patients. The trial is enrolling adul...